Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform
Date: May 21, 2026 Time: 11-12pm EDT / 5-6pm CEST Title: Bioanalysis of Oligonucleotide Therapeutics via Nucleic Acid Nanorobotic Platform Description: Dynamic DNA nanotechnology enables the isothermal and enzyme-free exchange of nucleic acid strands. The underlying mechanism of action in this ...
Immunogenicity Risk Assessment for Nucleic Acid Therapeutics
Date: October 1, 2026 Time: 11-12pm EDT / 5-6pm CEST Title: Immunogenicity Risk Assessment for Nucleic Acid Therapeutics: A Comprehensive Evaluation for ASO, siRNA, and Nonvaccine mRNA/LNP Therapies Description: Nucleic acid therapeutics require new immunogenicity evaluation frameworks, as the safety and ...
Trainee Spotlight Series: 2025 Oligo Meeting Poster Winners 6
Date: September 17, 2026 Time: 11-12pm EDT / 5-6pm CEST Title: Streamlining Exon-Skipping Antisense Oligonucleotide Therapy Development Via a High-Throughput Approach Description: Disease-modifying therapies are available for <5% of the >7000 described rare genetic diseases (RGDs). Antisense oligonucleotides (ASOs) represent a ...
Advancing Precision Medicine: Oligonucleotide Therapeutics and Genome Editing
Date: June 18, 2026 Time: 11-12pm EDT / 5-6pm CEST Title: Advancing Precision Medicine: Oligonucleotide Therapeutics and Genome Editing Description: The advent of programmable therapeutics — from oligonucleotide drugs to genome editing technologies — is transforming the treatment landscape for genetic ...
Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics
Date: June 4, 2026 Time: 11am-12pm EDT / 5-6pm CEST Title: Chance, Choice, and Conviction: A Career in Oligonucleotide Therapeutics Description: An insight into how a combination of (taking) chance, role models, mentors, becoming better at making informed decisions, and learning ...
Selection of DNA Aptamers to Inhibit TDP-43 Aggregation in ALS
Date: May 7, 2026 Time: 11-12pm EDT / 5-6pm CEST Title: Selection of DNA Aptamers to Inhibit TDP-43 Aggregation in ALS Description: Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease characterized by the loss of motor neurons. With an unknown ...
Trainee Spotlight Series: 2025 Oligo Meeting Poster Winners 5
Date: April 16, 2026Time: 11-12pm EDT / 5-6pm CEST Title: Development of an N=1 Therapeutic Antisense Oligonucleotide for a unique UNC13A variant Description: Rare disorders collectively affect 3 to 10% of the population, but treatment options are scarce. Recently, genetic variants ...
Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications
Date: April 2, 2026Time: 11-12pm EDT / 5-6pm CEST Title: Extended Nucleic Acid Therapeutics: Unlocking potential through tiny methylene chemical modifications Description: Modulation of the backbone structures of oligonucleotides has a profound impact on the pharmacokinetics and pharmacodynamics of RNA medicines. ...
Advancing Prime Editing–Based Genome Editing Technologies for Therapeutic Applications
Date: March 26, 2026 Time: 12-1pm EDT / 5-6pm CET Title: Advancing Prime Editing–Based Genome Editing Technologies for Therapeutic Applications Description: In this webinar, I will discuss recent advances in prime editing–based genome engineering, including split prime editing, template-jumping prime editing, ...
Meet the 2026 Trainee Reps
Date: March 19, 2026 Time: 12-1pm EDT / 5-6pm CET Title: A Trainee's Perspective: Advocacy & Research in ALS Description: In this talk, Daniel will introduce himself as one of the two newest trainee representatives on the OTS Board of Directors ...
